These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 19633100)

  • 21. Erythropoietin derivate improves left ventricular systolic performance and attenuates left ventricular remodeling in rats with myocardial infarct-induced heart failure.
    Xu K; George I; Klotz S; Hay I; Xydas S; Zhang G; Cerami A; Wang J
    J Cardiovasc Pharmacol; 2010 Nov; 56(5):506-12. PubMed ID: 20881614
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Expression of erythropoietin and its receptor in neuroblastomas.
    Sartelet H; Fabre M; Castaing M; Bosq J; Racu I; Lagonotte E; Scott V; Lecluse Y; Barette S; Michiels S; Vassal G
    Cancer; 2007 Sep; 110(5):1096-106. PubMed ID: 17647284
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Prognostic significance of erythropoietin and erythropoietin receptor in tongue squamous cell carcinoma.
    Li HG; Li JS; Chen WL; Wang L; Wu DH; Lin ZY
    Br J Oral Maxillofac Surg; 2009 Sep; 47(6):470-5. PubMed ID: 19559511
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Preventive effect of erythropoietin on cardiac dysfunction in doxorubicin-induced cardiomyopathy.
    Li L; Takemura G; Li Y; Miyata S; Esaki M; Okada H; Kanamori H; Khai NC; Maruyama R; Ogino A; Minatoguchi S; Fujiwara T; Fujiwara H
    Circulation; 2006 Jan; 113(4):535-43. PubMed ID: 16449733
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Erythropoietin and the nervous system.
    Genc S; Koroglu TF; Genc K
    Brain Res; 2004 Mar; 1000(1-2):19-31. PubMed ID: 15053948
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The role of anemia in the progression of congestive heart failure. Is there a place for erythropoietin and intravenous iron?
    Silverberg DS; Wexler D; Iaina A
    J Nephrol; 2004; 17(6):749-61. PubMed ID: 15593047
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The non-haematopoietic biological effects of erythropoietin.
    Arcasoy MO
    Br J Haematol; 2008 Apr; 141(1):14-31. PubMed ID: 18324962
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The Erythropoietin System Protects the Heart Upon Injury by Cardiac Progenitor Cell Activation.
    Zafeiriou MP
    Vitam Horm; 2017; 105():233-248. PubMed ID: 28629520
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The potential role of erythropoietin in chronic heart failure: from the correction of anemia to improved perfusion and reduced apoptosis?
    Timmer SA; De Boer K; Knaapen P; Götte MJ; Van Rossum AC
    J Card Fail; 2009 May; 15(4):353-61. PubMed ID: 19398085
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Erythropoietin protects the heart from ventricular arrhythmia during ischemia and reperfusion via neuronal nitric-oxide synthase.
    Burger DE; Xiang FL; Hammoud L; Jones DL; Feng Q
    J Pharmacol Exp Ther; 2009 Jun; 329(3):900-7. PubMed ID: 19307451
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Erythropoietin biology in cancer.
    Hardee ME; Arcasoy MO; Blackwell KL; Kirkpatrick JP; Dewhirst MW
    Clin Cancer Res; 2006 Jan; 12(2):332-9. PubMed ID: 16428469
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Erythropoietin and neuroprotection].
    Chatagner A; Hüppi PS; Ha-Vinh Leuchter R; Sizonenko S
    Arch Pediatr; 2010 Sep; 17 Suppl 3():S78-84. PubMed ID: 20728813
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Erythropoietin: a new perspective in cardiovascular therapy].
    Raddino R; Robba D; Caretta G; Bonadei I; Teli M; Zanini G; Madureri A; Vizzardi E; Dei Cas L
    Monaldi Arch Chest Dis; 2008 Dec; 70(4):206-13. PubMed ID: 19263796
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Erythropoietin receptor is expressed on human peripheral blood T and B lymphocytes and monocytes and is modulated by recombinant human erythropoietin treatment.
    Lisowska KA; Debska-Slizień A; Bryl E; Rutkowski B; Witkowski JM
    Artif Organs; 2010 Aug; 34(8):654-62. PubMed ID: 20528849
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Erythropoietin and myocardial protection: what's new?
    Joyeux-Faure M; Godin-Ribuot D; Ribuot C
    Fundam Clin Pharmacol; 2005 Aug; 19(4):439-46. PubMed ID: 16011730
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Overview of erythropoietin].
    Lacombe C; Mayeux P; Casadevall N
    Nephrologie; 1991; 12(5):221-6. PubMed ID: 1662784
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Coronary microvascular dysfunction: a key step in the development of uraemic cardiomyopathy?
    Radhakrishnan A; Pickup LC; Price AM; Law JP; Edwards NC; Steeds RP; Ferro CJ; Townend JN
    Heart; 2019 Sep; 105(17):1302-1309. PubMed ID: 31239278
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Growth hormone attenuates myocardial fibrosis in rats with chronic pressure overload-induced left ventricular hypertrophy.
    Moreira VO; Pereira CA; Silva MO; Felisbino SL; Cicogna AC; Okoshi K; Aragon FF; Padovani CR; Okoshi MP; Castro AV
    Clin Exp Pharmacol Physiol; 2009 Mar; 36(3):325-30. PubMed ID: 19278522
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Erythropoietin and the heart: facts and perspectives.
    Mastromarino V; Volpe M; Musumeci MB; Autore C; Conti E
    Clin Sci (Lond); 2011 Jan; 120(2):51-63. PubMed ID: 20929439
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Functional and metabolic adaptation in uraemic cardiomyopathy.
    Smith K; Semple D; Aksentijevic D; Bhandari S; Seymour AM
    Front Biosci (Elite Ed); 2010 Jun; 2(4):1492-501. PubMed ID: 20515820
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.